(P106) Switching to Tirzepatide 5 mg from GLP-1 RAs: Clinical Expectations in the First 12 Weeks of Treatment

This poster outlines a prospective study aimed to describe the clinical course in terms of changes in glycemic outcomes, body weight, and adverse event occurrence in the 12 weeks following a switch from GLP-1 RA to tirzepatide 5 mg, with the 2.5-mg initiation dose omitted.